Skip to Main Content
  • Become an Access Reviewer
  • Clinical Phenotypes
  • OMMBID Advisory banner
  • Ommbid banner
  • Ommbid latest banner

Abstract

Abstract 

  1. Lung cancer is the leading cause of cancer-related death for both men and women in the United States and the solid tumor with the most defined relationship to a known environmental cause, cigarette smoking. The clinical and biologic aspects of this disease are complex in that four major histologic cancer types, all related to smoking, can arise from the bronchial epithelium, including large cell undifferentiated, squamous cell, adeno-, and small cell lung carcinomas. The first three types, collectively known as non-small cell lung cancer (NSCLC), metastasize later than the small cell tumors (SCLC) and some cases can be cured by early surgery. SCLC is one of the most highly metastatic tumors in humans and has less than a 5 percent 5-year survival rate.

  2. There are no well-defined syndromes for inherited lung cancer. However, several genes confer genetic predisposition for development of lung cancer. These genes include the nicotinic acetylcholine receptor genes CHRNA3, CHRNA5 and CHRNB4, as well as several genes involved in the metabolism of carcinogens.

  3. Extensive studies have identified chromosomal regions commonly deleted or amplified in lung cancer, as well as specific genes commonly mutated or inactivated by DNA hypermethylation. Integrated analyses of these data have identified numerous genes that are commonly involved in the development of lung cancer; these genes include KRAS, the MYC family, EGFR, ERBB2, ALK, NKX2-1, TP53, CDKN2A/p16, RB1 and LKB1. Recent studies also implicate several microRNAs in lung cancer.

  4. There are excellent animal models for lung cancer. These models include both carcinogen induced and genetically modified models, in which the effects of specific genes and carcinogens in lung cancer can be explored, and targeted therapeutic strategies can be developed.

  5. Many of the genes implicated in lung cancer are associated with significant prognostic and therapeutic implications, and some, particularly EGFR and ALK, are already important therapeutic targets. We are on the edge of an exciting era in lung cancer therapy, in which knowledge of specific genetic lesions will dictate effective personalized therapy.

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Subscription Options

OMMBID Full Site: One-Year Subscription

Connect to the full suite of OMMBID content including new and revised chapters that reflect the latest research, image galleries, clinical phenotypes, and more.

$295 USD
Buy Now

Pay Per View: Timed Access to all of OMMBID

24 Hour Subscription $34.95

Buy Now

48 Hour Subscription $54.95

Buy Now

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.